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Abstract: In this work, we report  the  studies  of drug metabolism by xanthine oxidase 
(XOD)  with  electrochemical  techniques.  Firstly,  a  pair  of  stable,  well-defined  and  
quasi-reversible  oxidation/reduction  peaks  is  obtained  with  the  formal  potential  at  
−413.1 mV (vs. SCE) after embedding XOD in salmon sperm DNA membrane on the 
surface  of  pyrolytic  graphite  electrode.  Then,  a  new  steady  peak  can  be  observed  at  
−730 mV (vs. SCE) upon the  addition of 6-mercaptopurine (6-MP) to the electrochemical 
system, indicating the metabolism of 6-MP by XOD. Furthermore, the chronoamperometric 
response shows that the current of the catalytic peak located at −730 mV increases with 
addition  of  6-MP  in  a  concentration-dependent  manner,  and  the  increase  of  the 
chronoamperometric current can be inhibited by an XOD inhibitor, quercetin. Therefore, 
our results prove that XOD/DNA modified electrode can be efficiently used to study the 
metabolism of  6-MP, which may provide a convenient approach for in vitro studies on 
enzyme-catalyzed drug metabolism. 
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1. Introduction 
Drug  metabolism  is  a  process  that  transforms  drug  molecules  into  polar,  water-soluble  and 
excretable metabolites through enzymatically catalyzed reactions [1]. Studies on drug metabolism can 
provide plenty of information about the metabolic pathway of metabolic intermediate and individual 
differences  in  drug  response,  which  may  play  an  important  role  in  drug  development.  
In vitro methods, having the advantages of large-scale metabolite assay and assessment of species 
differences in metabolism, have been widely used for the studies of drug metabolism [2,3]. However, 
the traditional methods, like mass spectrometry  (MS) and high performance liquid chromatography 
(HPLC),  are  usually  time-consuming  and  expensive  [4,5].  Considering  the  importance  of  drug 
metabolism,  more  techniques  should  be  developed  for  the  studies  of  drug  metabolism,  and  an 
electrochemical technique,  which is of small size, quite  low  cost,  easy  to  operate  and  capable of 
continuous measurements, has attracted increasing attention for its application in the studies of drug 
metabolism. Electrochemical technique with extremely no toxicity can mimic the redox reactions of 
the biomolecules as well as the drug metabolism in the living organisms in vitro, and the electrode can 
be a favorable electron donor taking place of the conventional electron supply systems.  Moreover, 
electrochemical technique may identify the interaction between drug-metabolizing enzyme and the 
drug  molecules  in  real  time  and  efficiently  monitor  both  the  stable  metabolite  and  the  unstable 
intermediary products in a rapid and sensitive manner, which are much more difficult to realize by the 
traditional  methods.  Therefore, electrochemical technique has become a welcome alternative to the 
traditional methods for in vitro drug metabolism studies [6–11]. 
Xanthine oxidase (XOD) is a metalloprotein that catalyzes the purine catabolism and also of major 
medical  interest  as  a  target  of  many  drugs  against  several  diseases  in  humans,  such  as  gout, 
hyperuricaemia  and  chronic  heart  failure  [12].  Although  XOD  has  been  implicated  as  a  key  
oxidative  enzyme  to  construct  electrochemical  sensors  for  the  determination  of  hypoxanthine  and  
xanthine [13–15], no electrochemical  investigation has  been performed  on the studies  of the drug 
metabolism by XOD. In this work, by using a XOD/DNA modified pyrolytic graphite (PG) electrode, 
we have studied the catalysis of 6-mercaptopurine (6-MP) by XOD with electrochemical techniques. 
Compared  with  the  traditional  studies,  our  method  displays  a  remarkably  improved  performance, 
which is simple, fast and sensitive, so it may be very promising in the fields of clinical medicine and 
pharmacology in the future. 
2. Results and Discussion 
Our  previous  studies  have  proven  that  salmon  sperm  DNA  can  provide  a  desirable  membrane 
environment for facilitating the electron transfer between XOD and an electrode [16], so we have 
firstly examined the XOD/DNA modified PG electrode with cyclic voltammetry (CV). As shown in 
Figure 1, a pair of well-deﬁned, reversible oxidation/reduction peaks (Peak I) can be observed with the 
formal  potential  at  −413.1  mV  (vs.  SCE),  contributing  to  the  electron  transfer  between  the  
electro-active center of the immobilized XOD and the electrode. The peak separation of the peak pair 
is only 51.6 mV at the scan rate of 100 mV/s, which indicates a fast heterogeneous electron transfer Int. J. Mol. Sci. 2012, 13  4875 
 
 
process on the XOD/DNA modified electrode. As a comparison, no voltammetric peak can be obtained 
at the salmon sperm DNA alone modified PG electrode under the same condition. 
We have then chosen 6-MP, an anticancer drug for the treatment of acute lymphoblastic leukemia 
and inflammatory bowel disease [17–19], as the substrate of the enzyme to realize the electrochemical 
studies of drug metabolism by XOD. It can be observed from Figure 1 that, in the presence of 200 μM 
6-MP, a new reduction peak  (peak  II) appears at −730 mV (vs. SCE) on the XOD/DNA modified 
electrode, while no voltammetric response can  be obtained on the DNA alone modified electrode 
although 6-MP is added in the test solution. So, the appearance of the new peak may be attributed to 
the  metabolism  of  6-MP  by  XOD  and  the  generation  of  the  metabolite,  e.g.,  6-thiouric  acid. 
Meanwhile, the peak current of XOD (peak I) has a little decrease, which indicates that the binding of 
6-MP to XOD may inhibit the electron transfer between XOD and the electrode. Therefore, the CV 
studies have proven that salmon sperm DNA membrane can not only facilitate the electron transfer 
between XOD and the electrode, but also well maintain the native activity of XOD, and, moreover, the 
XOD/DNA modified electrode can be efficiently used to catalyze the metabolism of 6-MP. 
Figure  1.  Cyclic voltammograms obtained at DNA and xanthine oxidase (XOD)/DNA 
modified  electrode  in  the  absence  and  presence  of  200  μM  6-MP  in  0.1  M  pH  7.4 
phosphate buffers. Scan rate: 100 mV/s. 
 
We have further employed a more sensitive electrochemical method chronoamperometry to study 
the metabolism of 6-MP by XOD. Figure 2 shows the chronoamperometric responses obtained at the 
XOD/DNA and DNA modified electrode with the continuous addition of 6-MP. It can be observed that 
on the XOD/DNA modified electrode, the current of the peak located at −730 mV evidently increases 
with the addition of 6-MP in a concentration-dependent manner, while the current hardly changes on 
the  DNA  alone  modified  electrode.  Similar  to  CV  results,  this  phenomenon  indicates  that  the 
metabolism of 6-MP can be catalyzed by XOD/DNA modified electrode in a feasible way. Int. J. Mol. Sci. 2012, 13  4876 
 
 
Figure  2.  Chronoamperomograms  obtained  at  (a)  XOD/DNA  and  (b)  DNA  modified 
electrode in 0.1 M pH 7.4 phosphate buffers with injecting 200 μM 6-MP every 30 s. The 
detection potential was −730 mV. 
 
In order to understand more precisely about the metabolism of 6-MP by XOD, we have further 
studied the effect of an inhibitor of the enzyme, quercetin, on this metabolism process, which is a 
major representative of flavonols and a dietary antioxidant proposed as a mechanism for curing the 
diseases  related  with  XOD  [20,21]. Since the metabolism of 6-MP by XOD may be inhibited by 
quercetin, the peak current of the metabolite located at −730 mV should correspondingly decrease. 
Figure 3a is the cyclic voltammogram obtained at the XOD/DNA modified electrode with the addition 
of 200 μM 6-MP in the absence and presence of 200 μM quercetin. It has shown that the new catalytic 
peak at −730 mV has become indistinguishable in the presence of quercetin, suggesting a significant 
inhibition of quercetin on the catalytic activity of XOD. Furthermore, we have studied the inhibitory 
effect  with chronoamperometry. As shown in Figure 3b, the current of the catalytic peak for 2 mM  
6-MP at −730 mV obtained in the chronoamperomogram  does  indeed decrease in the presence of 
quercetin,  and  the  decrease  of  the  current  is  observed  to  be  stronger  with  a  higher  quercetin 
concentration.  So,  both  the  cyclic  voltammogram  and  chronoamperomogram  have  proven  the 
inhibitory effect of quercetin on the metabolism by XOD, and reconfirmed that the electrochemical 
technique can be used as a powerful in vitro method for the studies of drug metabolism. Int. J. Mol. Sci. 2012, 13  4877 
 
 
Figure  3.  (a)  Cyclic  voltammograms  obtained  at  XOD/DNA  modified  electrode  for   
200  μM  6-MP  in  the  absence  and  presence  of  200  μM  quercetin,  others  same  as  in   
Figure  1;  (b)  The  chronoamperometric  currents  obtained  at  the  XOD/DNA  modified 
electrode for 2 mM 6-MP in the presence of different concentrations of quercetin (0, 2, 10, 
100 μM) in 0.1 M phosphate buffer (pH 7.4). 
 
3. Experimental Section  
3.1. Reagents 
XOD, 6-MP, salmon sperm DNA and quercetin were obtained from Sigma. The solutions were 
prepared  with  double-distilled  water  (18  MΩ· cm),  which  was  purified  with  a  Milli-Q  ultrapure   
water system.   
3.2. Preparation of XOD/DNA Modified Electrode 
The substrate PG electrode was firstly polished using rough and fine sand papers. Then, it was 
polished to mirror smoothness with aluminum oxide (particle size of about 0.05 μm)/water slurry on 
silk. Finally, the electrode was thoroughly washed by ultrasonicating in both doubly distilled-water and 
ethanol for 5 min, respectively. Afterward, a mixture of 10 μL 3.5 U/mL XOD and 10 μL 1.0 mg/mL 
salmon sperm DNA solution was evenly spread on the surface of the PG electrode. The modified 
electrode  was  dried  overnight  at  room  temperature  in  the  dark,  and  was  thoroughly  rinsed  with   
double-distilled water before use. 
3.3. Electrochemical Measurements 
Electrochemical  experiments  were  performed  on  a  CHI  440a  electrochemical  analyzer   
(CH  Instrument), using  a  three-electrode  configuration.  The  reference  electrode  was  a  saturated 
calomel electrode (SCE) and the counter electrode was a platinum electrode. All the test solutions were 
bubbled thoroughly with high-purity nitrogen through the solution for at least 10 min. A stream of 
nitrogen was then blown gently across the surface of the solution to maintain the solution anaerobic 
throughout the experiments. Int. J. Mol. Sci. 2012, 13  4878 
 
 
4. Conclusions  
In summary, we have successfully demonstrated an electrochemical approach to study the drug 
metabolism  by  XOD.  While  DNA  membrane  on  the  PG  electrode  surface  can  well  maintain  the 
activity of XOD and facilitate the electron transfer process, both voltammetric and chronoamprometric 
results have proven the metabolism of 6-MP by XOD, which can be further prohibited by the XOD 
inhibitor, quercetin. Our electrochemical approach has overcome several drawbacks of the traditional 
methods for in vitro studies on drug metabolism, such as its laborious and time-consuming methods. 
Therefore, this approach may provide a new strategy for in vitro studies of drug metabolism that may 
facilitate drug development and clinical application in the future. 
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